Evolus has filed a material event (SEC 8-K) signaling aggressive marketing of Jeuveau (prabotulinumtoxinA) through its Evolus Rewards loyalty program, directly targeting medspa practices. The program offers rebates and volume incentives to shift market share from Allergan Aesthetics' Botox and Galderma's Dysport.
Jeuveau entered the U.S. market in 2019 as a faster-onset neuromodulator (onset in 24 hours vs. 3–7 days for Botox/Dysport) and has gained traction in medspas seeking differentiation. Evolus Rewards mirrors Allergan's Alle and Galderma's Aspire programs—loyalty schemes that bundle rebates, co-pay assistance, and practice incentives to lock in volume commitments. The intensity of these programs reflects margin compression across the neuromodulator category as supply normalizes and competition commoditizes pricing.